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Abstract – The inﬂuenza A nucleoprotein (NP) is an attractive target for avian ﬂu vaccine development
because of its high conversancy in the evolutionary chain of the virus. Here we identiﬁed two novel
HLA-A*0201 restricted NP epitopes, named H5N1 NP373-381 AMDSNTLEL (NP373) and NP458-466
FQGRGVFEL (NP458), using computational bioinformatic analysis. The NP peptides showed a high
binding afﬁnity to HLA-A*0201 on T2 cells, and were able to induce the activation of the cytotoxic T
cells in the human peripheral blood mononuclear cells. We examined the potential of using NP373 and
NP458 peptide sequences supplemented with a single-chain trimer as potential DNA vaccine candidates
in an HHD transgenic mouse model. A gene gun delivery system was used for administrating the vaccine
candidates into the animals. The results from cytotoxicity and ELISPOT assays indicated that a signiﬁcant
amount of IFN-c was secreted by the T cells of the vaccinated mice, and the T cells were able to
eliminate the corresponding peptide-loaded T2 cells. The discovery of these novel immunogenic NP
peptides provides valuable information for avian ﬂu vaccine design and construction.
inﬂuenza A virus / H5N1 nucleoprotein / HLA-A*0201 T-cell epitope / single-chain trimer / HHD
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1. INTRODUCTION
The transmission of a pathogenic avian
H5N1 virus from poultry to humans in Hong
Kong and other Asian countries has caused a
number of human deaths [13, 17, 19]. Con-
ﬁrmed cases of H5N1 transmission have also
been reported in various African and European
countries
1 and all incidences have caused an
enormous economic loss in the poultry indus-
tries worldwide. The threat of an H5N1 pan-
demic is becoming a major problem not only
in Asian countries but countries worldwide.
The urgency of developing a strategy to combat
the H5N1 virus is an imperative task for most
health authorities, and one possible solution is
to develop a human vaccine against the H5N1
virus.
The production of a neutralizing antibody is
the primary step to combat viral infection.
Anotherimportantmechanismforviruselimina-
tion is the initiation of a cell-mediated immune
response involving the induction of effector
CD8+ cytotoxic T lymphocytes (CTL). Con-
served components within the inﬂuenza A viral
genome are good targets for inducing CTL
responses because they can withstand viral
mutations and have the capability to induce
* Corresponding author: boyxie@ust.hk
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ent subtypes and variations [14, 15, 24].
Nucleoprotein (NP) generally binds to the
viral RNA and is synthesized in large amounts
during viral replication within the infected cells
[26]. In the inﬂuenza Avirus, NP is a compara-
tivelyconservedprotein,andthereisnorecorded
evolution in the viral strains of most birds over
the past 60 years. [26]. Therefore, because
of its high conservancy during the evolution of
the virus, NP is an attractive target for inducing
T-cell immunity [10, 26]. One of the promising
approaches involves a direct DNA vaccination
to stimulate T-cell immunity against NP.
Some DNAvaccines and recombinant viral vac-
cines such as those constituting an adenovirus
encodingthewholeNPgene,arefoundeffective
in eliciting the T-cell immunity [6, 7, 14, 23].
We previously showed that a single-chain
trimer (SCT) system is a promising system
for use in the construction of DNA vaccines
[2]. Here, we identiﬁed two novel HLA-
A*0201-restricted H5N1-NP-protein peptides
and a modiﬁed SCT system was used in vac-
cine construction. The efﬁcacy of the con-
structed vaccine candidates was investigated
in a special genetically modiﬁed HHD trans-
genic mouse model. Our results suggest that
the H5N1 NP373-381 AMDSNTLEL and
NP458-466 FQGRGVFEL peptides might be
promising candidates for use in H5N1 vaccine
construction.
2. MATERIALS AND METHODS
2.1. Peptide construction
H5N1 NP peptides from the H5N1-Thailand-
human-2004 strain were predicted by the HLA-
peptide-binding prediction program, SYFPEITHI
2.
Nine 9-mer potential peptides were synthesized by
solid-phasestrategies.TheywerenamedNP48KLSD-
YEGRL, NP55 RLIQNSITI, NP158 GMDPRMCSL,
NP189 MVMELIRMI, NP256L I F L A R S A L ,N P 2 7 5
CLPACVYGL, NP357 QLSTRGVQI, NP373
AMDSNTLEL,andNP458FQGRGVFEL.Apeptide
previously identiﬁed (N220 LALLLLDRL) was used
as a positive control [2].
2.2. Animal model
HHD transgenic H-2D
b-/- b2m
-/- double knockout
mice (6–8 weeks old) purchased from the Institute
Pasteur in France were bred and maintained
under pathogen-free conditions (Animal & Plant Care
Facility, HKUST, Hong Kong, China). HHD mice
were originally derived from C57BL mice with the
mouse b2-microglobulin and MHC I knock-out,
and HLA-A*0201 knock-in expressing the chimeric
HLA class-I molecules, which were composed of
the human b2-microglobulin, HLA-A*0201 a-1 and
a-2 domains and the a-3 domain of H-2D
b [21].
2.3. Production of recombinant NP
Recombinant NP was expressed from pET16b in
BL21-condon plus (DE3)-RIL cells (Stratagene, La
Jolla, CA, USA). Soluble NP was puriﬁed by a
His-Bind Kit (Novagen, San Diego, CA, USA) and
puriﬁed proteins were analyzed and conﬁrmed by
SDS-PAGE. Western blotting analysis was performed
using an anti-inﬂuenza A NP antibody (Chemicon,
Billerica, MA, USA).
2.4. T2-cell binding experiments
T2 cells (174 · CEM.T2, ATCC, Manassas, VA,
USA) were identiﬁed as HLA-A*0201 positive, and
they were transporters for the antigen-processing-
deﬁcient cells. The cells were maintained in IMDM
medium (Invitrogen, Carlsbad, CA, USA) supple-
mented with 5% FBS (Invitrogen), 100 U/mL peni-
cillin and 100 lg/mL streptomycin (Invitrogen) at
37  C with 5% carbon dioxide. In T2-cell binding
assays, the cells (1 · 10
5) were pulsed with each of
the target NP peptides (10 lg/mL), respectively, in
serum-free medium containing the human b2-micro-
globulin (5 lg/mL) for 2 h. The cells were washed
with 1· PBS, stained with an FITC-conjugated
anti-human HLA-A2 antibody (BD Pharmingen,
San Diego, CA, USA), and ﬁnally subjected to ﬂow
cytometrical analysis (BD FASC Aria II, BD Biosci-
ence, San Jose, CA, USA). The ﬂuorescent index
was calculated by the formula as follows: FI = [MFI
(T2 + peptide)/MFI (T2 only)]   1. The ﬂu peptide,
GILGFVFTL, was used as a positive control [1].
2.5. In vitro stimulation of human CD8+ T cells
Fresh human HLA-A2+ peripheral blood mono-
nuclear cells (PBMC) (Hong Kong Red Cross,
2 http://www.syfpeithi.de
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density gradient centrafugation (GE Healthcare,
Piscataway, NJ, USA). CD8+ T cells were puriﬁed
using human CD8 microbeads (MACS, Miltenyi
Biotec, Bergisch Gladbach, Germany) and primed
with autologous dendritic cells (DC) loaded with NP
[2, 16]. Brieﬂy, PBMC were seeded on 60 mm
dishes (BD Bioscience) for 2 h. The process for
DC culture requires 7 days. Adherent monocytes
were cultured in an AIM-V medium (Invitrogen)
containing GM-CSF (800 U/mL, Amoytop Biotech,
Xiamen, Fujian, China) and IL-4 (1 000 U/mL,
Amoytop Biotech) for 4 days. On day 5 from the cell
culturing process, 20 lg/mL of NP was added. On
day 6, maturation of DC was carried out by adding
TNF-a (10 ng/mL) and PGE2 (1 lg/mL, Sigma-
Aldrich Corp, St. Louis, MO, USA) to the culture
medium. On day 7, mature DC were co-cultured
with the puriﬁed CD8+ T cells in AIM-V medium
(Invitrogen) supplemented with 5% human AB
serum (Sigma-Aldrich Corp), IL-2 (20 U/mL,
Amoytop Biotech), and IL7 (10 ng/mL, Miltenyi
Biotec) for 7 days. The CD8+ Tcells were stimulated
three times with protein-loaded DC, respectively.
2.6. Staining of intracellular cytokines
Intracellular cytokine staining was performed as
previously described with minor modiﬁcations [28].
Brieﬂy, primed T cells were incubated with peptide-
loaded T2 cells in the presence of Brefeldin A (eBio-
science, San Diego, CA, USA) for 8 h. The cells
were stained with a PE-conjugated anti-human CD8
antibody (eBioscience) at 4  C for 30 min. After
washing with 1· PBS, the cells were ﬁxed and
permeabilized with a permeabilization buffer (eBio-
science) according to the manufacturer’s instructions.
T h ec e l l sw e r eﬁ n a l l ys t a i n e dw i t ha nF I T C - c o n j u -
gated anti-human IFN-c antibody at 4  C for 30 min
in the dark, and the ﬂuorescent signals were detected
by ﬂow cytometrical analysis (BD FASC Aria II, BD
Bioscience). T2 cells loaded with previously identi-
ﬁed non-responsive peptide (N160 LQLPQGTTL),
were used as a negative experimental control [2].
2.7. Construction of plasmids
Plasmids including NP158HHDpBudCE4.1, NP-
189HHDpBudCE4.1, NP373HHDpBudCE4.1, and
NP458HHDpBudCE4.1 were prepared as follows.
In brief, the single-chain trimer gene (HHD) was con-
structed by connecting the leader sequence, the
human b2-microglobulin, the human HLA-A*0201
a-1, a-2 domains, and the mouse H-2D
b a-3 domain.
It was subsequently cloned into a pBudCE4.1 vector
(Invitrogen). Plasmids encoding different peptide
sequences were constructed by adding the corre-
sponding DNA fragments after the leader sequence
of the HHD using PCR with the following primers:
sense (NP158: 50-ATCGACCGGTCTATATGCTGG
AATGGACCCTCGGATGTGTTCCCTGGGAGGA
GGTGCTAG-30, NP189: 50-ATCGACCGGTCTATA
TGCTATGGTGATGGAGCTGATCAGAATGATCG
GAGGAGGTGCTAG-30,N P 3 7 3 :5 0-ATCGACCGG
TCTATATGCTGCCATGGACAGCAACACCCTGG
AGCTGGGAGGAGGTGCTAG-30,N P 4 5 8 :5 0-ATC
GACCGGTCTATATGCTTTCCAGGGACGGGGA
GTGTTCGAGCTGGGAGGAGGTGCTAG-30)a n d
antisense (50-ATCGCTCGAGTCACGCTTTACAAT
C-30) primers. The constructed fragments were cloned
into HHDpBudCE4.1 at Age Ia n dXho Is i t e s .T h e
N220HHDpBudCE4.1 expressing an identiﬁed
HLA-A*0201 epitope (N220) was used as a control
plasmid [2].
2.8. Animal vaccination
Animal vaccination was carried out by a gene gun
delivery system and the preparation of DNA-coated
gold particle cartridges was performed as previously
described [2]. Brieﬂy, cartridges were prepared by
precipitating the plasmid DNA on 1 lm gold parti-
cles (Bio-Rad, Hercules, CA, USA) in 0.05 M sper-
midine (Sigma-Aldrich Corp) and 1 M CaCl2.T h e
microcarrier/DNA suspension mixed with polyvinyl-
pyrrolidone (5 mg/mL, Sigma-Aldrich Corp) was
coated into the plastic tubing. The coated tubing
was cut into 0.5 inch cartridges, and each cartridge
contained 1 lg of DNA. DNA-coated particles were
delivered to the shaved abdominal region of the HHD
mice using a Helios gene gun (Bio-Rad, Hercules,
CA, USA) with a discharge pressure of 400 psi.
The mice received DNA (1 lg) for each vaccination.
All animal groups (three mice per group) received a
total of three vaccinations at 1-week intervals.
2.9. Cytotoxicity assay
The cytotoxicity assay was performed using a
Delﬁa EuTDA cytotoxicity detection kit (Perkin-
Elmer, Waltham, MA, USA). Mice were sacriﬁced
1 week after the lastvaccination for splenocyte extrac-
tion. Splenocytes were cultured in an IMDM medium
(Invitrogen) supplemented with 5% FBS (Invitro-
gen), the corresponding target peptides (10 lg/mL),
and IL-2 (10 U/mL, eBioscience) in 12-well plates
(BD Bioscience) at 37  Cf o r5d a y s .T h e yw e r e
seeded with the TDA-labeled, peptide-loaded T2 cells
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mice immunized with N220HHDpBudCE4.1 were
used as an experiment control. The splenocytes
seeded with N220-loaded T2 cells were used as a
positive control while those seeded with N160-loaded
T2 cells served as a negative control [2]. After incu-
bating at 37  C for 1 h, the culture medium was
collected and the ﬂuorescent signals emitted by the
dead peptide-loaded T2 cells were detected with the
cytotoxicity reagents according to the procedures
stated by the manufacturer. The cytotoxicity was
determined by the following equation:
Cytotoxicity % ðÞ ¼
experimentalreleasevalue–spontaneousreleasevalue
maximumreleasevalue–spontaneousreleasevalue

  100
Two controls were set up for the cytotoxicity
assay: a maximum release was measured from the
peptide-loaded T2 cells lyzed by a lysis buffer, and
the spontaneous release was measured as a natural
release from the peptide-loaded T2 cells.
2.10. ELISPOT assay
An ELISPOT assay was performed as previ-
ously described with minor modiﬁcations [2]. Brieﬂy,
a 96-well nitrocellulose plate (MultiScreen-HA,
Millipore, Billerica, MA, USA) was coated with an
anti-mouse IFN-c antibody (5 lg/mL, eBioscience)
at 4  Cf o r2 0 hf o l l o w e db yb l o c k i n gw i t ha n
IMDM medium (Invitrogen) supplemented with 5%
FBS (Invitrogen) at 37  C for 2 h. Splenocytes
(1 · 10
6) were seeded into the four wells of a 96-well
nitrocellulose plate, and the corresponding target pep-
tides (10 lg/mL) were added. The plate was incu-
bated at 37  C for 24 h. The mice immunized with
N220HHDpBudCE4.1 were used as experiment con-
trols. The splenocytes with N220 peptide added were
used as positive controls while those added with
N160 peptide served as negative controls [2]. Subse-
quently, the plate was washed with 1· PBS contain-
i n g0 . 0 1 %T w e e n2 0a n di n c u b a t e dw i t ha
biotinylated anti-mouse IFN-c antibody (0.5 lg/mL,
eBioscience) at room temperature for 1 h. After
washing, a streptavidin-AP solution (1 lg/mL,
Sigma-Aldrich Corp) was added and the plate was
incubated at room temperature for 30 min. After a
ﬁnal wash, spots were developed by adding a
BCIP/NBT solution (Invitrogen) and the visible
spots were counted by an ELISPOT reader (Thermo
Labsystems, Franklin, MA, USA).
Two controls for each group of splenocytes were
set up for the ELISPOT assay. Splenocytes without
the addition of peptides were used as a negative con-
trol while the splenocytes with staphylococcal entero-
toxin B (Sigma-Aldrich Corp) added were used as a
positive control.
2.11. Statistical analysis
Statistical analysis was expressed as means ±
standard error (SE). A comparison between the indi-
vidual readings was performed using the student’s
t-test. p values < 0.05 were regarded as statistically
signiﬁcant.
3. RESULTS
In order to search for the immunogenic NP
peptide sequence, nine potential peptides were
predicted using SYFPEITHI software. Various
assays were used to determine the immunoge-
nicity of the peptides and the desirable ones
(i.e., those with both the highest binding
afﬁnity to HLA-A*0201 positive cells and the
ability to stimulate human CD8+ T cells) were
selected for further in vivo experimentation. In
order to determine their binding afﬁnity to
HLA-A*0201 positive cells, the peptides were
synthesized and a T2-cell binding assay was
performed. T2 cells normally express unstable
HLA molecules on the cell surface and there-
fore if a peptide is able to ﬁt into the peptide-
binding groove of an HLA molecule, it will
form a more stable structural complex with
the HLA molecule in the presence of b2-micro-
globulin. This complex can be detected with an
anti-human HLA-A2 antibody via ﬂow cytom-
etry. In our assay, a ﬂu peptide (GILGFVFTL),
which is an HLA-A*0201 epitope, was used as
a positive control for the experiment. The
results indicate that the NP373 (AMDSNT-
LEL), NP189 (MVMELIRMI), and NP458
(FQGRGVFEL) showed the highest scores in
the T2-cell binding assay (Fig. 1).
The potential of the nine peptides in stimu-
lating the human CD8+ T cells was also deter-
mined. Two groups of CD8+ T cells isolated
from PBMC of two healthy donors, respec-
tively, were primed with autologous mature
NP-loaded DC three times. Intracellular
Vet. Res. (2010) 41:24 Y.-K. Cheung et al.
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release of IFN-c from the CD8+ T cells, and
the peptide-loaded T2 cells were used as the tar-
get cells. NP once processed by DC, will com-
bine with the HLA molecules and eventually
become presented on the cell surface for the
priming of the CD8+ T cells. The primed
CD8+ Tcells could therefore recognize the pep-
tide-MHC complex on the T2 cells if the target
peptides are processed and presented on the DC
surface. The results from intracellular cytokine
staining showed that the highest number of
CD8+ IFN-c-secreting T cells was produced
after the stimulation with the NP189 (MVME-
LIRMI), NP373 (AMDSNTLEL), and NP458
(FQGRGVFEL) peptides, and the lowest num-
ber of the stimulated T cells was observed after
stimulation with the NP158 (GMDPRMCSL)
peptide. The N160 (LQLPQGTTL) peptide-
loaded T2 cells used as a negative control did
not show any signiﬁcant changes (Fig. 2)[ 2].
From the results of the two assays, we
selected four target peptides, NP158 (GMD-
PRMCSL), NP189 (MVMELIRMI), NP373
(AMDSNTLEL), and NP458 (FQGRGVFEL)
for animal experimentation. Based on our ﬁnd-
ings, three of the peptides showed the highest
binding afﬁnity to the HLA-A2 molecules and
they were able to activate the highest number
of CD8+ T cells. Since NP158 (GMDPR-
MCSL) exhibited a comparatively low ability
to stimulate T cells against the peptide-loaded
T2 cells and induced only a small amount of
the IFN-c release, it was included in the sample
peptides as a control for checking the consis-
tency of the results previously shown by the
in vitro T-cell stimulation experiment.
An animal experiment was performed to test
the immunogenicity of the target peptides
in vivo. DNA corresponding to the target
peptides was cloned into the HHD gene to pro-
duce a DNA vaccine candidate containing the
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Figure 1. A graph showing the results of the T2-cell binding assay. The binding afﬁnity of the NP peptides
to HLA-A2 in the presence of additional b2-microglobulin was detected by a T2-cell binding assay. T2 cells
were pulsed with the target NP peptides, respectively, in serum-free medium supplemented with the
b2-microglobulin for 2 h. The peptide-HLA-A2 complex was probed by an FITC-conjugated anti-human
HLA-A2 antibody and the ﬂuorescent signals were detected via ﬂow cytometry. The binding afﬁnity was
presented as the ﬂuorescent index that was calculated by the following formula: FI = [MFI (T2 + peptide)/
MFI (T2 only)]   1. The ﬂu peptide (GILGFVFTL) was used as a positive control. The results represent the
mean ± SE (n = 3).
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chain complex that could be expressed on the
cell surface and trigger the immune system.
Mice received a total of three administrations
and were sacriﬁced 1 week after the last injec-
tion. Splenocytes were collected for the cyto-
toxicity and ELISPOT assays.
Cytotoxicity was measured by the amount of
TDA released from the target cells. The target
cells (T2 cells) were loaded with the target
peptides. Therefore, the peptide-loaded T2 cells
would be killed if the corresponding peptides
were immunogenic to the mice. The results
from the cytotoxicity assay showed that the
highest percentage of cytotoxic response was
triggered in mice immunized with plasmids
encoding NP373 and NP458, and the effect
wassimilar tothat producedbythepositivecon-
trol (N220). During an 1 h incubation period,
NP373 exhibited a 14% and 10% killing efﬁ-
ciency with the effector cell-to-target cell ratios
of 50:1 and 10:1, respectively, and NP458
exhibited a 13% and 9% killing efﬁciency with
the effector cell-to-target cell ratios of 50:1 and
10:1, respectively. However, the killing efﬁ-
ciency of T cells triggered by the NP189 was
comparatively low (7%) with the effector cell-
to-target cell ratios of 50:1. The result produced
by NP158 was signiﬁcantly lower, with only a
3.7% killing efﬁciency at an effector cell-to-
target cell ratio of 50:1 (Fig. 3).
AnELISPOTassaywasusedtodeterminethe
splenocyterecognitionofthecorrespondingpep-
tides via IFN-c release after animal immuniza-
tion. The largest number of splenocytes
(appeared as spots) was produced in mice
after immunization with NP373 and NP458
containing the SCT-DNA constructs (79 and
72 spots, respectively). In contrast, only 14 and
4 spots were observed in animals immunized
with NP189 and NP158 containing the SCT-
DNA constructs, respectively. The results were
very similar to the negative control (5 spots
only). The immunogenicity triggered by
NP189 in mice was comparatively low when
compared with the results of the T2-cell binding
assay and the intracellular cytokine staining.
Nonetheless, the results indicate that the immu-
nogenicity of NP373 and NP458 was more than
18 times higher than that induced by NP158
(Fig. 4).
The prediction process was repeated and the
prediction score indicated that NP373 and
NP485 may be able to bind to a variety of other
HLA types, such as HLA-A1, A11, A24, A26,
B7, B8, B14, B15, B27, B37, B38, B39, B40,
B44, and B47 (Tab. I).
4. DISCUSSION
HLA-A*0201isaglobalcommonHLAtype,
which occurs at high frequencies in popula-
tions of northern and southeast Asia and North
America[18].Inthisstudy,weselectedninepep-
tides that might be potential vaccine candidates
for human inﬂuenza A using the HLA-peptide-
bindingprediction program.Two novel epitopes
for HLA-A2 speciﬁc H5N1 NP were found,
namely NP373-381 AMDSNTLEL (NP373)
and NP458-466 FQGRGVFEL (NP458). We
further repeated the prediction process to
investigate the binding of the two identiﬁed
epitopes to other HLA types (Tab. I). We
Figure 2. An illustration of intracellular cytokine staining due to the secretion of IFN-c from human
CD8+ T cells. CD8+ T cells were primed with autologous NP-loaded DC three times at 1-week intervals.
Primed CD8+ T cells were cultured with different target peptide-loaded T2 cells for 8 h and the number of
IFN-c-secreting CD8+ T cells was stained with PE-conjugated anti-human CD8 and an FITC-conjugated
anti-human IFN-c antibodies, and subsequently subjected to ﬂow cytometry. A negative control was set up
using T2 cells added with previously identiﬁed non-responsive peptide (N160). (A) Representative data from
ﬂowcytometricalanalysisofoneofthetwoexperimentsperformedfortheﬁrstdonor.(B)Agraphshowingthe
data from two individual experiments for the ﬁrst donor only. (C) Representative data from ﬂow cytometrical
analysisofoneofthetwoexperimentsperformedfortheseconddonor.(D)Agraphshowingthedatafromtwo
individual experiments for the second donor only. The p values were calculated by the student’s t-test
(*p < 0.05) on comparisons between sample data points and the negative control data point.
c
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bind to other HLA types, and therefore further
experimentation may be required to conﬁrm
the prediction.
An ideal vaccine capable of counteracting
infectious viruses should be able to trigger both
neutralizing antibody production and the
cytotoxic T-cell response which are critical
processes in eliminating the virus during a viral
pathogenesis. As previously mentioned, current
studies of H5N1 vaccines have mainly focused
on the generation of neutralizing antibodies
[3, 11]. Another research stream involves the
study of cell-mediated immunity against
H5N1. Epitopes have been found in different
internal proteins of inﬂuenza virus and with
different HLA types [9, 20, 22, 25].
Amongst the identiﬁed epitopes, all NP epi-
topes are categorized as HLA-B types. We
decided to examine the NP epitope binding
speciﬁcity of HLA-A*0201 to CD8+ T cells.
A desirable peptide sequence for inducing cyto-
toxic T-cell response should be presented as an
endogenous peptide epitope through protea-
some digestion and have a high binding afﬁnity
towards human MHC class-I molecules. There-
fore, apart from the T2-cell binding assay, the
stimulating ability of the predicted peptides
was also accessed via an in vitro stimulation
using human PBMC. In vitro stimulation was
carried out by priming the T cells with the nat-
urally processed NP peptides from autologous
DC. Our results showed that the NP189 peptide
stimulated the strongest immune response
amongst the four peptides used. The binding
afﬁnity of NP158 in the T2-cell binding assay
was relatively high but no signiﬁcant change
in the immune response was observed during
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Figure 3. A graph showing the percentage of speciﬁc killings of the target peptide-loaded T2 cells after
immunization. Mice were immunized with NP158HHDpBudCE4.1, NP189HHDpBudCE4.1,
NP373HHDpBudCE4.1, NP458HHDpBudCE4.1, and N220HHDpBudCE4.1, respectively, by gene gun
delivery for three times at 1-week intervals. One week after the last immunization, splenocytes were
collected and cultured with the corresponding peptides for 5 days. The splenocytes were subsequently
incubated with the corresponding TDA-labeled peptide-loaded T2 cells at ratios of 50:1, 10:1, and 2:1,
respectively, for 1 h. The culture media were collected and the ﬂuorescent signals from the dead peptide-
loaded T2 cells were detected by a Delﬁa EuTDA cytotoxicity detection kit and the cytotoxicity was
calculated. The x-axis indicates the different ratios of the effector cells (splenocytes) to the target cells
(TDA-labeled peptide-loaded T2 cells). The y-axis indicates the percentage of cell cytotoxicity. The
cytotoxicity for the six groups of splenocytes vaccinated with the various plasmids was indicated as follows:
NP158HHDpBudCE4.1 (--), NP189HHDpBudCE4.1 (-j-), NP373HHDpBudCE4.1 (-d-), and
NP458HHDpBudCE4.1 (-4-). N220HHDpBudCE4.1 (-h-) was used as a positive control. Splenocytes
obtained from the mice vaccinated with the plasmid, N220HHDpBudCE4.1, but tested with N160-loaded
T2 cells (-m-), was used as a negative control. The results represent the mean ± SE (n = 3).
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the result produced was similar to the negative
control. This suggests that the peptide predic-
tion software can only give a computational
estimation of immunogenicity of potential vac-
cine candidates. Hence, the predicted epitopes
may not truly reﬂect experimental conditions
in vitro nor mimic the real state in vivo.
Natural processing and peptide presenta-
tion on the HLA molecule signiﬁcantly contrib-
ute to the magnitude of the immune response
[5, 8]. In our experiment, the number of
CD8+ Tcells detected via intracellular cytokine
staining was not as high as expected compared
to the whole pool of CD8+ T cells. In normal
natural processing, all epitopes on NP-loaded
DC are presented to the CD8+ T cells, based
on the cross-presentation characteristics of
the DC [4, 16, 27]. Therefore all activated
CD8+ T cells should be responsive to the
immunogenic epitopes presented on NP. In
our experiment, our target cells were loaded
with only a single type of the target peptide
which may explain why such a low percentage
of cell activation caused by the corresponding
peptide-speciﬁc CD8+ T cells is observed.
We used an SCT approach to construct our
peptide vaccine candidates. With this method,
peptides are able to speciﬁcally bind to the pep-
tide-binding cleft created by the HLA-A*0201
a-1 and a-2 domains, and this phenomenon
can imitate the natural binding of peptides onto
the MHC class-I molecules during normal anti-
gen processing [12]. Also the SCT system
ensures the stability of the MHC I-peptide com-
plexaftertranslation[29],andamorepreciseand
direct priming of the professional antigen pre-
senting cells to the cytotoxic Tcells is achieved.
Hence the stimulating efﬁciency of the peptide
vaccine can be greatly maximized [2].
The selected peptides were tested for their
cytotoxic T cell stimulating ability in vivo
using a HHD transgenic mouse model. HHD
is a special mouse type which lacks mouse
b2-microglobulin and MHC I, but contains
human b2-microglobulin and HLA-A*0201
a-1, a- 2 ,a sw e l la sam o u s ea-3 fusion gene.
This genetically modiﬁed mouse immune
0 20 40 60 80 100
N P158
N P189
N P373
NP458
N220
160
Spots/250000 Splenocytes
* 
*
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Figure 4. A graph presenting the results of the ELISPOT assay. Mice were immunized with
NP158HHDpBudCE4.1, NP189HHDpBudCE4.1, NP373HHDpBudCE4.1, and NP458HHDpBudCE4.1
by gene gun delivery three times at 1-week intervals. N220HHDpBudCE4.1 was used as a positive control.
One week after the last immunization, the splenocytes were collected and cultured with corresponding
peptides for 24 h. The secretion of IFN-c was measured by the ELISPOT assay. The N160 peptide
(LQLPQGTTL) was used as a negative control for the assay with the mice vaccinated with
N220HHDpBudCE4.1. The results represent the mean ± SE (n = 4). The p values were calculated by
the student’s t-test (*p < 0.05) on comparisons between sample data points and the negative control data
point.
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immune response to stimulation restricted to
the reaction between HLA-A*0201 and T-cell
receptors only, eliminating the background
caused by mouse MHC class-I molecules [21].
In our experiment, cytotoxicity and ELISPOT
assays showed that the NP373-381 AMDSNT-
LEL and NP458-466 FQGRGVFEL are the
most immunogenic peptides. The reactivity of
the two peptides was consistent with all the tests
during the process of epitope identiﬁcation.
Another target peptide, NP189, although it
showed good responses in the T2-cell binding
assay and in vitro stimulation of human CD8+
T cells, it induced a weak response in animal
experiments. This is another indication that the
in vitro system does not reﬂect the in vivo situ-
ation. Nonetheless, in vitro experiments are
essential for acquiring basic information to ver-
ify the characteristics of these potential peptides
anddiscoveredimmunogenicpeptides,sincethe
testing of the peptides cannot be performed in
clinical trials without extensive investigation.
The T2-cell binding assay is a good methodol-
ogy for examining the potential binding afﬁnity
of the target peptides to the groove of HLA-
A*0201 molecules. The antigen processing
and presentation, and the magnitude of the
CD8+ T-cell responses corresponding to the
stimulants can be investigated via in vitro stim-
ulation of the CD8+ Tcells. We believe that the
HHD transgenic mouse model is an appropriate
animal model for investigating the stimulating
effects of the peptide-HLA complex to the cor-
responding T-cell responses.
In summary, we identiﬁed two novel HLA-
A*0201 T-cell epitopes, NP373 and NP458,
in the H5N1 viral NP. Our results indicate that
these two epitopes are capable of inducing a
strong immune response, and that the SCT sys-
tem can improve the immune responses. The
ﬁnding of these novel cytotoxic T-cell epitopes
presented provides signiﬁcant information for
the development of a human H5N1 vaccine.
Table I. Prediction scores of the NP373 and NP485 peptides for the binding to other HLA types via a
HLA-peptide-binding prediction program, SYFPEITHI
2.
HLA Type Score
NP373 AMDSNTLEL NP485 FQGRGVFEL Flu peptide
a GILGFVFTL
A*01 15 3 1
A*0201 25 19 30
A*1101 15 2 13
A*2402 10 12 14
A*26 11 12 17
B*0702 16 12 13
B*08 11 13 16
B*1402 17 16 18
B*1501 2 12 7
B*1510 12 13 14
B*2705 13 14 19
B*2709 13 11 16
B*37 13 12 17
B*3801 16 13 13
B*3901 19 13 15
B*3902 12 19 13
B*4001 17 13 13
B*4402 17 12 14
B*4701 10 10 13
B*4901 11 7 9
a The ﬂu peptide (an epitope of HLA-A*0201) is used as a reference for the comparison of the binding scores.
HLA-A2 T-cell epitopes in H5N1 nucleoprotein Vet. Res. (2010) 41:24
(page number not for citation purpose) Page 11 of 13In the future, experiments using a mixture of
SCT-DNA constructs encoding H5N1 NP epi-
topes instead of using one type of SCT-DNA
construct encoding a single peptide are neces-
sary to investigate whether there are any
improvements for the immunogenicity.
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